Showing results (1271-1280 of 1,302) with videos related to
Sort By:
Pageof 131
The New England Journal of Medicine|May 16, 2019
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined SourceHans-Christoph Diener, Ralph L Sacco, J Donald Easton, et al.Cancer Immunology Research|October 11, 2019
Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGFMariangela Di Tacchio, Jadranka Macas, Jakob Weissenberger, et al.The Journal of Clinical Endocrinology and Metabolism|June 23, 2012
A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral densityEric Orwoll, Christence S Teglbjærg, Bente L Langdahl, et al.The Journal of Pharmacology and Experimental Therapeutics|January 10, 2008
Correlating efficacy in rodent cognition models with in vivo 5-hydroxytryptamine1a receptor occupancy by a novel antagonist, (R)-N-(2-methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexane carboxamide (WAY-101405)Warren D Hirst, Terrance H Andree, Suzan Aschmies, et al.The Journal of Pharmacology and Experimental Therapeutics|October 16, 2009
WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activityJulie A Brennan, Radka Graf, Steven M Grauer, et al.Journal of Neuro-Oncology|January 7, 2023
Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trialJ Weller, N Schäfer, C Schaub, et al.Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 11, 2000
Summary report of the TD-3 workshop: characterization of 83 antibodies against prostate-specific antigenU H Stenman, E Paus, W J Allard, et al.Neuro-Oncology|October 1, 2024
Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with lomustine/temozolomideThomas Zeyen, Laura Böhm, Daniel Paech, et al.Clinical Spine Surgery|May 1, 2018
Frequency and Acceptability of Adverse Events After Anterior Cervical Discectomy and Fusion: A Survey Study From the Cervical Spine Research SocietyJefferson R Wilson, Kris Radcliff, Gregory Schroeder, et al.Bioorganic & Medicinal Chemistry Letters|September 2, 2009
Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophreniaDavid P Rotella, Geraldine R McFarlane, Alexander Greenfield, et al.Pageof 131